From the American Academy of Ophthalmology
News from the FSO
Live News from the 2012 American Academy of Ophthalmology Meeting
Don’t combine routine corneal cross-linking (CXL) with primary LASIK. This was the contention of Perry S. Binder, MD, during a session at the Refractive Surgery meeting on Friday. “Do not perform corneal cross-linking on primary LASIK cases until we can determine the risk and benefits. If in doubt about a possible high-risk case, consider PRK or a phakic IOL.”
News from the 2012 American Academy of Ophthalmology Meeting
At a media briefing today, Michael X. Repka, MD, MBA, Academy medical director for Governmental Affairs, announced that the Centers for Medicare & Medicaid Services has implemented a physician fee schedule cut effective Jan. 1 of approximately 13.5 percent for cataract surgery. This estimate could change if Congress allows the SGR reduction to take effect.
More news from the 2012 American Academy of Ophthalmology Meeting
In an overview of recent advances, speakers made it clear that oculoplastics isn’t what it used to be.
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
This analysis of data from the Fuchs Endothelial Corneal Dystrophy Genetics Multi-Center Study shows that index cases and affected family members with severe disease (grade 4-6) had a higher prevalence of glaucoma and/or ocular hypertension relative to control subjects or unaffected family members. The authors suggest considering periodic glaucoma assessments when monitoring these patients, particularly those with moderate to advanced disease. Archives of Ophthalmology, November 2012
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
First-year results of two phase 3 studies comparing intravitreal aflibercept, monthly or every two months, with monthly ranibizumab show that aflibercept can potentially decrease the treatment and compliance burden of anti-VEGF treatment. Results show aflibercept dosed monthly or every two months after three initial monthly doses resulted in similar visual and anatomic outcomes as ranibizumab dosed monthly, and with a similar safety and tolerability profile. Ophthalmology, December 2012
Pages
Upcoming Events
In the News...
